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THE ADDITION OF BEVACIZUMAB,a monoclonal antibody againstvascular endothelial growthfactor, to cytotoxic chemo-
therapy is associated with improved
survival in patients with stage IV colo-
rectal cancer and higher pathologic
response rates in patients undergoing re-
section of colorectal liver metastases.1,2
Response to bevacizumab, which ex-
erts an antiangiogenic mechanism of ac-
tion, may be inadequately assessed by
traditional size-based radiologic crite-
ria, the Response Evaluation Criteria in
Solid Tumors (RECIST), which were de-
signed for assessing tumor volume re-
duction following cytotoxic chemo-
therapy.3-5 In support of this, a recent
phase 3 trial showed that the addition
of bevacizumab to oxaliplatin-based che-
motherapy for metastatic colorectal can-
cer improved progression-free survival
without affecting RECIST-defined re-
sponse rates.6
Recently, pathologic response to pre-
operative chemotherapy has been
shown to correlate with improved sur-
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Context The standard criteria used to evaluate tumor response, the Response Evalu-
ation Criteria in Solid Tumors (RECIST), were developed to assess tumor shrinkage af-
ter cytotoxic chemotherapy andmay be limited in assessing response to biologic agents,
which have a cytostatic mechanism of action.
Objective To validate novel tumor response criteria based on morphologic changes
observed on computed tomography (CT) in patients with colorectal liver metastases
treated with bevacizumab-containing chemotherapy regimens.
Design, Setting, and Patients A total of 234 colorectal liver metastases were ana-
lyzed from 50 patients who underwent hepatic resection after preoperative chemo-
therapy that included bevacizumab at a comprehensive US cancer center from 2004
to 2007; date of last follow-upwasMarch 2008. All patients underwent routine contrast-
enhanced CT at the start and end of preoperative therapy. Three blinded, indepen-
dent radiologists evaluated images for morphologic response, based on metastases
changing from heterogeneous masses with ill-defined margins into homogeneous hy-
poattenuating lesions with sharp borders. These criteria were validated with a sepa-
rate cohort of 82 patients with unresectable colorectal liver metastases treated with
bevacizumab-containing chemotherapy.
Main Outcome Measures Response determined using morphologic criteria and
RECIST was correlated with pathologic response in resected liver specimens and with
patient survival.
Results Interobserver agreement for scoring morphologic changes was good among
3 radiologists (, 0.68-0.78; 95% confidence interval [CI], 0.51-0.93). In resected tu-
mor specimens, the median (interquartile range [IQR]) percentages of residual tumor
cells for optimal morphologic response was 20% (10%-30%); for incomplete re-
sponse, 50% (30%-60%); and no response, 70% (60%-70%; P .001).With RECIST,
the median (IQR) percentages of residual tumor cells were for partial response 30%
(10%-60%); for stable disease, 50% (20%-70%); and for progressive disease, 70%
(65%-70%; P=.04). Among patients who underwent hepatic resection, median over-
all survival was not yet reached with optimal morphologic response and 25 months
(95% CI, 20.2-29.8 months) with incomplete or no morphologic response (P=.03).
In the validation cohort, patients with optimal morphologic response hadmedian over-
all survival of 31months (95%CI, 26.8-35.2months) compared with 19months (95%
CI, 14.6-23.4 months) with incomplete or nomorphologic response (P=.009). RECIST
did not correlate with survival in either the surgical or validation cohort.
Conclusion Amongpatientswith colorectal livermetastases treatedwith bevacizumab-
containing chemotherapy, CT-based morphologic criteria had a statistically signifi-
cant association with pathologic response and overall survival.
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vival and has been proposed as a new
outcome end point after resection of co-
lorectal liver metastases.7-9 To date, a
noninvasive method of predicting
pathologic response to chemotherapy
in colorectal liver metastases, particu-
larly biologic agents, is lacking. We
observed that after bevacizumab-
containing therapy, colorectal liver me-
tastases tend not only to decrease in size
but also to undergo unique morpho-
logic changes on computed tomogra-
phy (CT). Metastases that have hetero-
geneous attenuation, variable degree of
enhancement, and ill-defined borders
before treatment transform into homo-
geneous, hypoattenuating lesions with
well-defined borders.
We hypothesized that these changes
on CT reflect the pathologic response in
patients treated with bevacizumab-
containing chemotherapy before hepatic
resection of colorectal liver metastases.
To test this hypothesis, we correlated tu-
mor response based on these morpho-
logic criteria and tumor response based
onRECISTwithpathologic response.We
then tested the morphologic criteria in
patientswithunresectable colorectal liver
metastases treated with bevacizumab.
The morphologic criteria and RECIST
were correlated with survival in pa-
tients who underwent resection and
those who did not.
METHODS
Initial Patient Cohort
From a prospective hepatobiliary da-
tabase at the University of Texas M. D.
Anderson Cancer Center, we identi-
fied 234 colorectal liver metastases in
50 consecutive patients who received
first-line chemotherapy with bevaci-
zumab before undergoing hepatic re-
section between March 2004 and March
2007. All patients underwent contrast-
enhanced CT scans of the abdomen at
the start and end of preoperative
therapy as part of their standard evalu-
ation. Patients who had undergone
prior liver resection were excluded.
Postoperatively, patients were fol-
lowed up with history and physical ex-
amination, CT scans, and serum car-
cinoembryonic antigen levels at 3- to
6-month intervals for the first 2 to 3
years after resection and at more ex-
tended intervals thereafter. The me-
dian follow-up time was 18 months
(range, 3-42 months). Date of last fol-
low-up was March 2008. This study in-
volved retrospective review of medi-
cal information and was conducted
under the approval of the institutional
review board, which waived the re-
quirement for informed consent.
Validation Patient Cohort
From a prospective gastrointestinal
medical oncology database at the Uni-
versity of Texas M. D. Anderson Can-
cer Center, we identified 82 patients
with unresectable colorectal liver me-
tastases treated with bevacizumab com-
bined with cytotoxic chemotherapy be-
tween March 2004 and April 2007.
Patients were considered unresectable
if 2 contiguous hepatic segments could
not be preserved, vascular inflow and
outflow or biliary drainage was inad-
equate, or the volume of the future liver
remnant was 20% or less of the total es-
timated liver volume.10 All patients un-
derwent contrast-enhanced CT scans of
the abdomen before starting chemo-
therapy and at 2- to 3-month intervals
thereafter. Median follow-up was 25
months (range, 6-57 months). Date of
last follow-up was April 2009.
Imaging Analysis
Computed tomographic scans were per-
formed with 4- or 16-slice CT (Light-
Speed, GE Healthcare, Piscataway, New
Jersey) using a collimation of 5 mm and
reconstruction at 2.5 mm. Images were
acquired with 1 of 2 methods: a tripha-
sic liver protocol following a noncon-
trast evaluation of the liver or a single-
phase technique. For the triphasic liver
protocol, images were obtained 30, 50,
and 70 seconds after the start of intra-
venous injection of ioversol at a rate of
5 mL/s. For the single-phase tech-
nique, images were obtained 60 to 70
seconds after the start of ioversol in-
jection at a rate of 2 to 3 mL/s. Be-
cause of the routine concomitant ac-
quisition of chest CT scans and delayed
images through the kidneys, single-
phase scans also permitted partial evalu-
ation of the liver during the early and
delayed phases of enhancement.
Response to treatmentwasassessed in-
dependently by 3 radiologists with 2, 15,
and 20 years of experience in abdomi-
nal oncologic imaging. Radiologists were
blinded to pathologic results, patient
treatment, and outcomes. Discrepan-
cies between radiologists were resolved
by consensus review. Response was
evaluated using new morphologic crite-
ria, assigning each metastasis to 1 of 3
groups (TABLE 1). A group-3 metasta-
sis was characterized by heterogeneous
attenuation and a thick, poorly defined
tumor-liver interface (FIGURE1A and C).
A group-1 metastasis was character-
ized by homogeneous low attenuation
with a thin, sharply defined tumor-
liver interface (Figure 1B). A group-2
metastasis had morphology that could
not be rated as 3 or 1 (Figure 1D).
When present, a peripheral rim of hy-
perattenuating contrast enhancement
was designated a group-3 characteris-
tic, and resolution of this enhance-
ment was classified group 1.
Morphologic response criteria were
defined as optimal if the metastasis
changed from a group 3 or 2 to a 1, in-
complete if the group changed from 3 to
2, and none if the group had not changed
or increased. In patients with multiple
tumors, morphologic response criteria
Table 1. Computed Tomographic Morphologic Groups
Morphology
Group
Computed Tomographic Tumor Characteristics
Overall Attenuation
Tumor-Liver
Interface Peripheral Rim of Enhancement
3 Heterogeneous Ill defined May be present
2 Mixed Variable If initially present, partially resolved
1 Homogeneous and
hypoattenuating
Sharp If initially present, completely resolved
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were assigned based on the response seen
in the majority of tumors. Response by
RECIST was defined as previously de-
scribed: complete response, disappear-
ance of all tumors; partial response, more
than a 30% decrease in sum of the long-
est diameter of target tumor; progres-
sive disease, more than a 20% increase
in the sum of the longest diameter of tar-
get tumor; and stable disease, none of the
complete response, partial response, or
progressive disease criteria met.11 The ap-
pearance of new metastases was de-
fined as progression by RECIST and mor-
phology assessment.
Assessment of Pathologic
Response to Chemotherapy
Hematoxylin and eosin−stained speci-
mens sectioned into 5-mm-thick slices
were evaluated by a gastrointestinal pa-
thologist who was blinded to treatment
regimen, radiologic results, and patient
outcomes. The extent of residual carci-
nomawasassessedsemiquantitativelyas
apercentagerelativetothetotaltumorsur-
facearea,aspreviouslydescribed.2,8Patho-
logicresponsewasscoredasminorif50%
or more of residual tumor cells were
present, major with 1% to 49% residual
tumor cells, and complete if no residual
tumor cells were detected.
Statistical Analysis
Continuous variables were compared
using the Kruskal-Wallis or Mann-
Whitney test; discrete variables, ex-
pressed as number and percentage, were
compared using the 2 test or Fisher ex-
act test, when appropriate. A post hoc
power analysis showed that based on the
actual number of patients enrolled in the
current study, therewasgreater than95%
statistical power to detect a difference in
a pathologic response rate of 32% be-
tween patients with optimal vs incom-
plete or no morphologic response at a
conventional P value of .05.  Statistics
were used to determine interobserver
agreement of the proposed morpho-
logic criteria among 3 radiologists.
Survival was determined from time of
hepatic resection until the time of death
or last follow-up. If more than 3 months
had lapsed since the date of last follow-
up, then survival was calculated accord-
ing to whether patients were alive at the
time the study was closed, as recorded
in tumor registry data or medical rec-
ords. Five patients with residual disease
in the liver, lung, or an intact primary
tumor at the time of hepatectomy were
excluded from the survival analysis.
Among patients with unresectable
tumors, survival was calculated from the
start of bevacizumab-containing chemo-
therapy. Survival curves were gener-
atedusingtheKaplan-Meiermethod,and
differences were evaluated with the log-
rank test. Analyses were performed with
SPSS software (version 12.0, SPSS Inc,
Chicago, Illinois).All statistical testswere
2-sided, and significance was set at
P .05.
RESULTS
Initial Surgical Cohort
Two hundred thirty-four lesions in 50
patients were evaluated; their demo-
graphic and clinicopathologic charac-
teristics are presented inTABLE 2. Of the
130 CT scans reviewed, 53 were per-
formed with triphasic liver protocol and
77 with the single-phase technique.
Among the 33 patients with multiple tu-
mors, the morphologic responses of the
metastases within the same patient were
concordant in all but 2 patients.
Morphologic response was signifi-
cantly associated with the percentage of
residual tumor cells: median (interquar-
tile range [IQR]) values were 70% (60%-
70%) for patients with no response, 50%
(30%-60%) for patients with incom-
plete response, and 20% (10%-30%) for
patients with optimal response (P.001,
FIGURE 2A). RECIST was also signifi-
cantly associated with the percentage
of residual tumor cells: median (IQR)
values were 70% (65%-70%) for pa-
tients with progressive disease, 50%
Figure1.RepresentativePretreatmentandPosttreatmentComputedTomographic ScansEvaluated
by Response Evaluation Criteria in Solid Tumors (RECIST) and Morphologic Criteria
A B
PosttreatmentPretreatment
PosttreatmentPretreatment
RECIST-stable disease and morphologic incomplete response
RECIST-stable disease and morphologic optimal response
C D
Arrowheads indicate the tumor-liver interface. Morphologic optimal response is characterized by decreased
attenuation and sharp tumor-liver interface (B); morphologic incomplete response is characterized by de-
creased attenuation but persistent ill-defined tumor-liver interface remaining after treatment (D).
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(20%-70%) for patients with stable dis-
ease, and 30% (10%-60%) for patients
with partial response (P=.04, Figure 2).
Whenpathologic responsewas strati-
fied as minor, major, or complete using
previously determined cutoff values for
the percentage of residual tumor cells,8
2 patients had a complete response, 27
had a major response, and 21 had a mi-
nor response. Metastases with major
pathologic response were characterized
by replacement of tumor cells by fibro-
sis.Necrosiswasobservedinlessthan5%
oftumors.Completeormajorpathologic
response corresponded to morphologic
optimal response in 22 of 29 patients
(76%),whileminorpathologic response
wasassociatedwithmorphologicpartial
ornoresponsein17of21patients(81%).
When correlated with RECIST, com-
plete or major pathologic response cor-
respondedtoRECISTpartial response in
23 of 29 patients (79%), while minor
pathologic responsewasassociatedwith
RECIST stable or progressive disease in
10 of 21 patients (48%). None of the pa-
tients had RECIST complete response.
Therefore, incompleteornoresponseby
morphology was more specific for pre-
dicting minor pathologic response than
RECISTstableorprogressivedisease(17
of 21, morphology vs 10 of 21, RECIST,
P=.02). Morphologic optimal response
and RECIST partial response had simi-
lar sensitivities for predicting complete
or major pathologic response (22 of 29,
morphologyvs23of29,RECIST,P=.75).
Patients Who Underwent Resection
Thirtypatients (60%)haddisease recur-
rence during the study period, and 9
(18%)diedofdisease.Fivepatients(10%)
with residual disease in the liver, lung,
or an intact primary tumor at the time of
hepatectomywereexcludedfromthesur-
vival analysis. Patients with optimal re-
sponse by morphology were classified
as responders while the remaining pa-
tients were classified as nonresponders.
When morphologic criteria were used
in tumor response evaluation, median
overall survival was not yet reached for
responders and 25 months for nonre-
sponders (95%confidence interval [CI],
20.2-29.8 months; P=.03, FIGURE 3).
When RECIST were used, median over-
all survival was not yet reached in pa-
tientswhoachievedpartial responseand
34monthswithstableorprogressivedis-
ease (95%CI,20.0-48.0months;P=.25,
Figure 3). On univariate analysis of tra-
Table 2. Baseline Characteristics
No. (%) of Patients
Initial
Surgical Cohort
(n = 50)
Patients With
Unresectable Tumor
(n = 82)
Age, median (range), y 57 (34-84) 57 (26-69)
Sex
Female 21 (42) 37 (45)
Male 29 (58) 45 (55)
Primary tumor
Colon 36 (72) 63 (77)
Rectum 14 (28) 19 (23)
Sites of metastases
Liver only 48 (95) 45 (55)
Liver and extrahepatic 2 (4) 37 (45)
Liver metastases
Solitary 17 (34) 4 (5)
Multiple 33 (66) 78 (95)
Tumor size, median (range), cma 2.3 (0.4-13) 4.9 (1.5-18.0)
Chemotherapy
FOLFIRI with bevacizumab 7 (14) 47 (57)
FOLFOX with bevacizumab 43 (86) 35 (43)
Hepatectomy
Minor 24 (48) NA
Major 26 (52) NA
Radiofrequency ablation at time of hepatectomy 8 (16) NA
No. of chemotherapy cycles before
hepatectomy, median (range)
6 (3-12) NA
Interval between last CT and surgery,
median (range), d
18 (2-56) NA
Overall survivalb
Median, mo Not reached 25
3 years, % 51 24
Abbreviations: CT, computed tomography; FOLFIRI, infusional fluorouracil (FU) and leucovorin with irinotecan; FOLFOX,
infusional FU and leucovorin with oxaliplatin; NA, not applicable.
aBased on the largest diameter of the resected tumor specimen in surgical patients and largest diameter on prechemo-
therapy computed tomography in unresectable patients.
bFrom time of hepatectomy in surgical cohort and from start of bevacizumab-containing chemotherapy in unresectable
cohort.
Figure 2. Correlation Between Morphologic Response or Response Evaluation Criteria in
Solid Tumors (RECIST) and Percentage of Residual Tumor Cells
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Lines inside boxes represent the median; end points of whiskers represent minimum and maximum values.
Lower and upper edges of boxes represent 25th and 75th percentiles. P values were derived from the Kruskal-
Wallis test comparing the percentage of residual tumor cells among patients with optimal, incomplete, or no
morphologic response; and RECIST partial response, stable disease, or progressive disease.
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ditional predictors of survival and po-
tential radiologicpredictorsofoutcome,
onlymorphologiccriteriademonstrated
asignificantcorrelationwithoverall sur-
vival (TABLE 3).
Validation in Patients
With Unresected Tumors
To validate the CT response criteria in
assessing clinically significant tumor re-
sponse of liver metastases, a separate co-
hort of 82 patients with unresectable co-
lorectal liver metastases treated with
bevacizumab-containing chemo-
therapy was analyzed. Their clinico-
pathologic features are presented in
Table 2. Among the 78 patients with
multiple liver metastases, the morpho-
logic responses of the metastases within
the same patient were concordant in all
but 10 patients; in these patients, the
morphology score was assigned based on
the dominant pattern observed.
Among the 82 patients with stage IV
colorectal cancer treated with chemo-
therapyonly,thosewithoptimalresponse
bymorphologiccriteriahadsignificantly
better overall survival than patients
withincompleteornoresponse,withme-
dian overall survival of 31 months (95%
CI, 26.8-35.2 months) and 19 months
(95%CI,14.6-23.4months),respectively
(P=.009,Figure3). Incontrast, response
byRECISTwasnotassociatedwithanim-
provementinsurvival.Medianoverallsur-
vival was 28 months (95% CI, 22.5-33.5
months) inpatientswithpartial response
and 22 months (95% CI, 15.3-28.7
months) in those with stable or progres-
sivedisease(P=.45,Figure3).Thefollow-
ing variables did not significantly affect
overallsurvival:sex,age,sizeormultiplic-
ity of hepatic metastases, rectal primary
tumor, and the presence of extrahepatic
metastases.
Interobserver Agreement
for Morphologic Criteria
The interobserveragreementbetween the
3 radiologists for scoring morphologic
changes was good:,0.78 (95% CI, 0.63-
0.93) between readers 1 and 2; , 0.72
(95% CI, 0.56-0.88) between readers 1
and 3; and , 0.68 (95% CI, 0.51-0.85)
between readers 2 and 3. Among the ra-
diologists, there were discrepancies in
scoring morphologic criteria in 13 of the
50 surgical patients, which were re-
solved by consensus review.
COMMENT
We present novel qualitative morpho-
logic CT criteria for predicting re-
sponse to bevacizumab-containing che-
motherapy in patients with colorectal
liver metastases. These criteria were re-
producible, as shown by the good in-
terobserver agreement in scoring mor-
phologic changes among 3 independent
radiologists with varied experience in ab-
dominal oncologic imaging. Morpho-
logic criteria correlated strongly with the
percentage of residual tumor cells and
also with pathologic response stratified
as complete, major, or minor using 50%
residual tumor cells as the cutoff value
between major and minor pathologic re-
sponse. Optimal morphologic response
to preoperative therapy translated into
a survival benefit after hepatic resec-
tion. In a separate validation cohort of
Figure 3. Overall Survival in Responders and Nonresponders by Morphologic Criteria and
Response Evaluation Criteria in Solid Tumors (RECIST) in the Initial Surgical Cohort and in
Patients With Unresectable Tumor (Validation Cohort)
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Survival was evaluated in 45 surgical patients who underwent complete resection.
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patientswithunresectable colorectal liver
metastases, response by morphologic cri-
teria was also associated with improved
overall survival. RECIST was also sen-
sitive for predicting complete or major
pathologic response but with a signifi-
cantly lower specificity for predicting mi-
nor pathologic response. RECIST was
associated with neither the stratified
pathologic response nor survival.
Optimalmorphologicresponsewasde-
fined as a change in metastases from le-
sionswithheterogeneousattenuationand
thick,irregularbordersintobland,homo-
geneouslyhypodensemasseswithasharp
interfacebetweenthetumorandadjacent
normal liverparenchyma,whichinsome
cases could mimic a cyst. This homoge-
neousattenuationofmetastasesrespond-
ingtotreatmentlikelyreflectsthereplace-
mentof treatedtumorbyfibroconnective
tissue rather than tumornecrosis,which
waspresent in less than5%ofpatients in
this study. Rubbia-Brandt et al7 also ob-
served that histological tumor response
is characterized by fibrous replacement
oftumorratherthantumornecrosisinco-
lorectal livermetastases. Inpatientswith
multiplelivermetastases,themorphologic
responses of the metastases within the
same patient were uniform in 99 of 111
patients(89%).Thisresultconfirmsapre-
viousstudydemonstratingthatinpatients
withmultiplecolorectal livermetastases,
the histological tumor responses within
the same patient were similar.7
The effect of pathologic response to
preoperative therapy on survival in
patients with solid tumors is well-
established.12,13 In patients with colorec-
tal liver metastases, histological tumor
regression, graded by the extent of fibro-
sis and presence of residual tumor cells,
has been shown to correlate with sur-
vival.7 In this study, we scored patho-
logic response semiquantitatively as the
percentage of residual tumor cells rela-
tive tothetotal tumorsurfacearea.Patho-
logicresponsewasscoredasminor if50%
or more of residual tumor cells were pre-
sent, major with 1% to 49% residual
tumorcells,andcompletewith0%.Using
this 50% cutoff to define major vs minor
pathologic response,werecently showed
that in patients with colorectal liver
metastases,majorpathologic response to
preoperative chemotherapy indepen-
dently predicted improved patient sur-
vival.8 In the present study, overall sur-
vival was correlated with morphologic
response but not RECIST-based prog-
nostic factors, such as tumor size and
number. Although the sample size in the
surgical cohort is small, these results
highlight the importance of response
rather than baseline clinical factors in
determining patient outcome after liver
resection.8,14
The limitations of this study include
its retrospective nature and potentially
thepredominantuseof a single-phaseCT
technique. Although triphasic liver pro-
tocol CT is not required to apply the mor-
phologic criteria and is probably not
needed routinely in nonsurgical pa-
tients with colorectal liver metastases, it
might improve sensitivity by allowing
evaluation of early and delayed phases
of tumor enhancement. Recent studies
on evaluating response to antiangio-
genic agents with CT or magnetic reso-
nance imaging have focused on tumor
perfusion.15-18 Although tumoral en-
hancement was a component of our mor-
phology response criteria, the degree of
enhancement could not be consistently
assessed because of variations in scan-
ning techniques. While colorectal liver
metastases are considered hypovascu-
lar tumors, enhancement does occur and
is characterized by an ill-defined rim of
peripheral enhancement that is maxi-
mal during the arterial phase and fades
Table 3. Univariate Analysis of Predictors of Overall Survival Among 45 Surgical Patients
Variable
No. of
Patients
Actuarial 2-Year
Survival Rate, % P Value
Sex
Male 26 79
.71
Female 19 74
Age, y
60 17 71
.83
60 28 89
Primary site
Colon 33 78
.24
Rectum 12 76
Primary tumor
Node negative 16 83
.90
Node positive 29 74
Prehepatectomy serum CEA, ng/mL
200 45 77
NA
200 0
Resection margin
Negative 43 79
.11
Positive 2 50
Disease-free interval, mo
12 15 69
.55
12 30 81
No. of tumors
1 16 75
.79
1 29 78
Tumor size, cma
5 40 79
.11
5 5 50
Morphologic response
Optimal 22 90
.03
Incomplete or none 23 42
RECIST
Partial response 31 80
.25
Stable or progressive disease 14 64
Abbreviations: CEA, carcinoembryonic antigen; NA, not applicable; RECIST, Response Evaluation Criteria in Solid Tumors.
aBased on the largest diameter of the resected tumor specimen.
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away during the portal phase.19,20 We re-
viewed many CTs that were single-
phase studies, lacking an arterial phase.
Nevertheless, in cases for which an early
hyperattenuating rim of enhancement
was present before treatment, it disap-
peared in all patients with an optimal
morphologic response. In addition, the
applicability of these criteria in assess-
ing response to other biologic agents ap-
proved for colorectal liver metastases re-
quires investigation.
In conclusion, we present novel quali-
tative radiologic criteria that predict the
pathologic response to preoperative
bevacizumab-containing chemo-
therapy in patients undergoing resec-
tion of colorectal liver metastases. Mor-
phologic response correlated with
pathologic response stratified as com-
plete, major, or minor, as well as over-
all survival, whereas RECIST did not.
This correlation between survival and
morphologic response, but not RECIST,
was confirmed in a nonsurgical cohort.
Thus, our results indicate that morpho-
logic response may be a useful, nonin-
vasive surrogate marker of pathologic re-
sponse and improved survival in patients
with colorectal liver metastases receiv-
ing a bevacizumab-containing regi-
men. It provides complementary infor-
mation to traditional size-based criteria
in assessing CT response to bevaci-
zumab in colorectal liver metastases
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